Cadexomer Iodine in Wound Care: Uses, Biofilms, and Safety

Cadexomer iodine is a wound-care product built around tiny starch beads that absorb fluid and slowly release iodine into the wound bed, combining physical cleaning with antimicrobial action. Unlike older iodine preparations that dump a concentrated dose all at once, cadexomer iodine meters out low levels of iodine over an extended period, which makes it effective against bacteria (including antibiotic-resistant strains and biofilms) while remaining gentle on healing tissue. It has been used in clinical practice since the 1980s, primarily for chronic wounds like venous leg ulcers and diabetic foot ulcers, yet it remains underappreciated relative to flashier wound technologies.

What Cadexomer Iodine Actually Is

The product starts with a chemically modified starch shaped into tiny hollow microspheres, each roughly 0.1 to 0.3 millimeters in diameter, with small holes in the outer shell. Iodine is physically trapped inside these beads at a concentration of about 0.9%.¹ That 0.9% figure is worth noting because it is far lower than the iodine concentrations in traditional antiseptics like povidone-iodine solutions, which typically range from 5% to 10%. The low starting concentration is central to how cadexomer iodine manages to kill bacteria without damaging the cells your body needs for wound repair.

You’ll encounter it in a few commercial forms: an ointment, a powder, and sheet dressings (often sold under the brand name Iodosorb). The differences between formats are mostly about convenience and wound shape. The underlying chemistry is the same across all of them.

How It Works in a Wound

Cadexomer iodine does two things at once, and both matter. First, when the beads contact wound fluid, they swell and absorb exudate. A systematic review noted that cadexomer beads can absorb up to seven times their own weight in fluid.² That swelling physically lifts dead tissue, pus, and debris away from the wound surface, acting as a kind of passive debridement. Second, as the beads swell and break down, they gradually release free iodine into the wound environment. This sustained release keeps iodine present in the wound for up to about 72 hours per application, rather than delivering a brief spike that fades quickly.

The rate of iodine release is governed by how fast water diffuses into the bead matrix. Research on the kinetics of this process found that water absorption into cadexomer iodine ointment follows a predictable pattern where diffusion into the starch matrix is the rate-limiting step.³ In practical terms, this means the iodine release is self-regulating: wetter, more heavily exuding wounds trigger faster bead swelling and more iodine release, while drier wounds get a lighter dose. The dual property of cleaning and disinfecting in one product is what sets cadexomer iodine apart from dressings that only absorb or only kill germs.⁴

Effectiveness Against Drug-Resistant Bacteria and Biofilms

One of the strongest arguments for cadexomer iodine is its performance against bacteria that shrug off conventional antibiotics. A controlled study evaluating cadexomer iodine dressings on acute wounds colonized with MRSA found that the dressing significantly reduced both MRSA counts and total bacterial counts compared to untreated controls and vehicle-only dressings.⁵ Further laboratory and animal model work demonstrated that cadexomer iodine showed superior efficacy against staphylococcal biofilms, including MRSA biofilms, across multiple testing methods.⁶

Biofilms are a particular headache in chronic wound care. When bacteria form a biofilm, they encase themselves in a sticky matrix that makes them far harder to kill than free-floating bacteria. Many antibiotics that work perfectly well in a lab dish fail against the same organism once it has established a biofilm in a wound. Cadexomer iodine appears to have an edge here. A study using porcine wound models showed significant biofilm reductions following cadexomer iodine treatment in both laboratory and animal settings.⁷ The mechanism likely involves iodine’s indiscriminate approach to killing microbes: it attacks multiple cellular targets simultaneously through oxidation, which makes it difficult for organisms to develop resistance through a single genetic mutation.

Clinical Evidence in Venous Leg Ulcers

The strongest body of clinical evidence for cadexomer iodine comes from venous leg ulcer trials, which makes sense given that these ulcers are common, slow to heal, and frequently complicated by bacterial colonization. A multicenter crossover study of 75 patients found that ulcers healed more than twice as fast with cadexomer iodine compared to standard therapy. Patients also showed trends toward less pain, less exudate, less pus, and faster development of granulation tissue (the new connective tissue that forms during healing).⁸

A controlled trial published in the British Medical Journal compared cadexomer iodine with standard dressings and found that the epithelium of ulcers dressed with cadexomer iodine grew back significantly faster.⁹ Another trial comparing cadexomer iodine paste with hydrocolloid dressings and paraffin gauze found that among patients treated for a full 12 weeks, ulcer area shrank by about two-thirds with cadexomer iodine versus roughly one-fifth with hydrocolloid dressings. The weekly rate of healing was also significantly higher for cadexomer iodine than for paraffin gauze.¹⁰

A systematic review and meta-analysis that pooled results from comparative clinical trials concluded that chronic wounds treated with cadexomer iodine were more than twice as likely to heal as those receiving standard care. Across studies, cadexomer iodine also produced a greater mean wound area reduction after eight weeks of treatment.¹¹

Evidence in Diabetic Foot Ulcers

Diabetic foot ulcers present different challenges than venous leg ulcers. Blood supply to the feet is often compromised, and the bacterial communities in diabetic wounds tend to be more complex, with multiple species coexisting in biofilm form. The evidence for cadexomer iodine in this setting is more recent and somewhat thinner than the venous ulcer data, but it points in a positive direction.

A prospective multicenter study of cadexomer iodine in diabetic foot ulcers tracked bacterial load and wound size over six weeks. By the end of the study period, bacterial counts had dropped significantly, and median wound surface area had fallen by about half. Wound depth also decreased by roughly 50% from baseline.¹² A separate study examining cadexomer iodine’s effect on the microbial communities in diabetic foot ulcers found that treatment achieved meaningful reductions in microbial load in a majority of samples and also shifted the composition and diversity of the bacterial communities in the wound.¹³

One interesting finding from research comparing two-week and six-week courses of cadexomer iodine in diabetic foot ulcers was that most of the microbial load reduction happened early. About three-quarters of samples achieved a meaningful drop in bacteria, and extending treatment from two to six weeks did not produce a statistically significant additional reduction in total microbial load. All ulcers in both groups showed initial reductions in wound size.¹⁴ This suggests that cadexomer iodine does its heaviest antimicrobial lifting in the first couple of weeks, though the wound-healing benefits of continued exudate management and debridement may persist.

How It Compares to Other Antimicrobial Wound Products

The two antimicrobial wound products clinicians most frequently compare to cadexomer iodine are silver-based dressings and povidone-iodine. Each comparison reveals a slightly different picture.

A randomized controlled trial comparing cadexomer iodine and nanocrystalline silver on leg ulcers found that overall healing rates and the number of wounds that closed were comparable between the two. Silver did show an advantage during the first two weeks, and in wounds that were larger, older, or more heavily exuding.¹⁵ So silver may have a speed advantage at the outset in certain wound profiles, while cadexomer iodine catches up over longer treatment courses. The choice between them sometimes comes down to wound characteristics and cost considerations rather than a clear winner on efficacy alone.

The comparison with povidone-iodine is more straightforward. Povidone-iodine releases iodine in a burst and lacks the exudate-absorbing starch matrix, so it provides neither the sustained antibacterial action nor the physical cleaning effect. Cadexomer iodine has consistently shown better promotion of granulation tissue, greater biofilm and debris reduction, and more effective wound healing than povidone-iodine preparations in the chronic wound literature.¹⁶ The two are not interchangeable despite both containing iodine as the active agent.

Safety and Side Effects

The most commonly reported side effect of cadexomer iodine is a transient burning or stinging sensation in the wound at the time of application. In a multicenter controlled trial, burning pain accounted for a large share of reported adverse events, with irritation and itching also occurring. Most events were mild, and serious adverse events were rare and unrelated to the product.¹⁷ Another multicenter trial noted the same: except for occasional mild local burning, no adverse effects were seen.¹⁸

A common concern with any iodine-containing wound product is whether enough iodine gets absorbed through the skin to affect thyroid function. This is a legitimate question, especially for patients with large wounds where more iodine could potentially enter the bloodstream. A randomized trial in patients with large chronic venous ulcers found that while blood levels of protein-bound iodine did rise during treatment, actual thyroid function tests showed no changes associated with cadexomer iodine use.¹⁹ That said, cadexomer iodine is contraindicated in people with known thyroid disorders (particularly Hashimoto’s thyroiditis and Graves’ disease), in children, in pregnant or breastfeeding women, and in anyone with a known iodine allergy. These are standard precautions for all iodine-based wound products.

The cytotoxicity profile is also reassuring. Lab work on human fibroblasts, the cells responsible for building new connective tissue in a wound, showed that cadexomer iodine at concentrations up to 0.45% was non-toxic. There were no changes in cell viability, shape, ability to multiply, or ability to produce collagen.²⁰ The slow-release mechanism keeps the free iodine concentration in the wound bed low enough to kill bacteria without harming the patient’s own cells. This distinguishes it from older iodine preparations, which at full strength can damage healthy tissue and delay healing.

Cost and Frequency of Dressing Changes

Cadexomer iodine products tend to cost more per unit than simple gauze or basic antiseptic ointments, which can make clinicians and patients hesitate. But the total cost picture looks different when you account for fewer dressing changes and faster healing.

A health-economic modeling study of chronic venous leg ulcers estimated that treatment with cadexomer iodine over one year cost about $7,259 per patient compared with $7,901 for standard care alone. Patients treated with cadexomer iodine had a higher healing rate (about 61% healed versus 54% with standard care) and gained roughly six additional ulcer-free weeks over the year.²¹ A separate analysis of diabetic cavity foot ulcers found that cadexomer iodine ointment achieved comparable clinical outcomes to standard topical treatments while carrying considerably lower weekly treatment costs, driven mainly by the reduced frequency of dressing changes and fewer staff visits required.²²

Because the beads continue to absorb fluid and release iodine over a period of roughly three days, dressings typically need changing only every two to three days rather than daily. In a healthcare system where nursing time and home visits are among the largest costs of chronic wound management, that reduction in visit frequency adds up quickly.

Why Bacterial Resistance Is Not a Concern

One of the most appealing features of cadexomer iodine in an era of rising antibiotic resistance is that bacteria do not appear to develop resistance to iodine. A review of iodine-based products for chronic wound care stated plainly that resistance to iodine antiseptics is unknown.²³ The reason has to do with how iodine kills. Antibiotics typically target a single bacterial process, like building a cell wall or copying DNA, and bacteria can evolve around that single point of attack. Free iodine, by contrast, is a broad oxidizing agent that disrupts proteins, lipids, and nucleic acids simultaneously. A bacterium would need to mutate multiple defense systems at once to survive, which is vanishingly unlikely.

This makes cadexomer iodine a particularly sensible choice for wounds that have already failed antibiotic therapy or that are colonized with multi-drug-resistant organisms. It also means repeated use in the same patient over weeks or months does not carry the same resistance-breeding risk as prolonged courses of topical antibiotics.

Practical Limitations and Who Should Avoid It

Cadexomer iodine is not a universal wound treatment. It performs best in moderately to heavily exuding wounds because the beads need fluid to swell and release iodine. On dry wounds, it will not activate properly and can be difficult to remove. If a wound has dried out or moved past the inflammatory and proliferative phases into final remodeling, switching to a different dressing type is appropriate.

There is also a practical ceiling on how much wound surface area you should treat at once. Most product guidelines recommend not exceeding about 50 grams of cadexomer iodine per application and not using it continuously for more than three months, to keep total iodine absorption within safe limits. These limits are more conservative than what the thyroid-function data might strictly require, but they provide a reasonable safety margin, especially for older adults or anyone with borderline thyroid health.

People with a known sensitivity to iodine should obviously avoid it. And while the burning sensation on application is typically brief and mild, it can be distressing enough for some patients that they prefer an alternative. In wounds where pain is already a significant quality-of-life issue, the brief flare of stinging may outweigh the benefits for individual patients, even if the product would otherwise be a good clinical fit.